Current Overview of Scientific Production on Therapies and Treatments Against Helicobacter pylori: Article of Review Scientometric
DOI:
https://doi.org/10.18041/2619-4465/interfaces.1.13392Keywords:
Helicobacter pylori, Therapies, Treatments, Scientometrics, Antibiotic resistanceAbstract
Helicobacter pylori infection represents a significant public health concern due to its high global prevalence and strong association with gastrointestinal diseases, including chronic gastritis, peptic ulcers, and gastric cancer. Despite the growing scientific interest in this bacterium, no recent scientometric review had focused exclusively on the therapies and treatments aimed at its eradication. This study conducted a scientometric analysis of scientific production from 2004 to 2024, using the Web of Science and Scopus databases. A total of 1,128 unique articles were identified and analyzed using tools such as Python, Gephi, and Inkscape to visualize trends, collaboration networks, and the evolution of knowledge. The results show a steady growth in publications, with China and the United States leading scientific production. Authors such as Malfertheiner P. and Graham D.Y. stand out as key figures in the field, while journals such as Helicobacter and World Journal of Gastroenterology are the main dissemination media. Network analysis identified central themes such as antibiotic resistance, bismuth quadruple therapies, and the role of probiotics as adjuvants. This study provides a structured overview of advances in H. pylori treatment, offering a solid foundation for researchers and healthcare professionals to identify priority areas and guide future research toward the development of more effective and personalized therapies.
Downloads
References
[1]B. Zhong et al., “Impact of Helicobacter pylori infection on neoadjuvant chemotherapy in locally advanced gastric cancer: a retrospective analysis,” BMC Cancer, vol. 25, no. 1, p. 157, Jan. 2025, doi: 10.1186/s12885-025-13494-5.
[2]M. S. Hemeda et al., “Efficacy of Cerebroplacental Doppler Ratio in Predicting Adverse Fetal Outcomes in Cases of Fetal Growth Restriction Multicenter Study,” J Clin Ultrasound, May 2025, doi: 10.1002/jcu.24076.
[3]M. S. Hemeda et al., “Investigation of metronidazole resistance-associated mutations and virulence genotypes in helicobacter pylori isolates from the Egyptian population: A cross-sectional study,” J Infect Chemother, vol. 31, no. 2, p. 102533, Feb. 2025, doi: 10.1016/j.jiac.2024.10.001.
[4]H. Sati et al., “The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance,” Lancet Infect Dis, Apr. 2025, doi: 10.1016/S1473-3099(25)00118-5.
[5]S. Zhang et al., “Fucoidan-modified antibiotic-free nanovesicles: A multidimensional approach to eradicate intracellular and extracellular Helicobacter pylori and restore gastrointestinal homeostasis,” Int J Biol Macromol, vol. 307, no. Pt 2, p. 141786, May 2025, doi: 10.1016/j.ijbiomac.2025.141786.
[6]J. Cao et al., “Fucoidan from sea cucumber cooking liquid: Structural analysis, physicochemical properties, and anti-Helicobacter pylori potential,” Int J Biol Macromol, vol. 306, no. Pt 4, p. 141593, May 2025, doi: 10.1016/j.ijbiomac.2025.141593.
[7]Q. Sun et al., “infection: a dynamic process from diagnosis to treatment,” Front Cell Infect Microbiol, vol. 13, p. 1257817, Oct. 2023, doi: 10.3389/fcimb.2023.1257817.
[8]A. Elbehiry et al., “Infection: Current Status and Future Prospects on Diagnostic, Therapeutic and Control Challenges,” Antibiotics (Basel), vol. 12, no. 2, Jan. 2023, doi: 10.3390/antibiotics12020191.
[9]S. Yang, S. Hao, H. Ye, and X. Zhang, “Cross-talk between and gastric cancer: a scientometric analysis,” Front Cell Infect Microbiol, vol. 14, p. 1353094, Jan. 2024, doi: 10.3389/fcimb.2024.1353094.
[10]V. K. Singh, P. Singh, M. Karmakar, J. Leta, and P. Mayr, “The journal coverage of Web of Science, Scopus and Dimensions: A comparative analysis,” Scientometrics, vol. 126, no. 6, pp. 5113–5142, Jun. 2021, doi: 10.1007/s11192-021-03948-5.
[11]S. O’Hern and N. Estgfaeller, “A scientometric review of powered micromobility,” Sustainability, vol. 12, no. 22, p. 9505, Nov. 2020, doi: 10.3390/su12229505.
[12]L. Xu, C. Ao, B. Liu, and Z. Cai, “Ecotourism and sustainable development: a scientometric review of global research trends,” Environ Dev Sustain, vol. 25, no. 4, pp. 2977–3003, 2023, doi: 10.1007/s10668-022-02190-0.
[13]C. Yu, J. Qiu, M. Xiong, C. Ou, M. Zeng, and H. Song, “Trends in -related gastric ulcer research from 2012 to 2022: A bibliometric and visual analysis,” Front Med (Lausanne), vol. 9, p. 1027534, Nov. 2022, doi: 10.3389/fmed.2022.1027534.
[14]C. Yuan et al., “Research on antibiotic resistance in : a bibliometric analysis of the past decade,” Front Microbiol, vol. 14, p. 1208157, Jun. 2023, doi: 10.3389/fmicb.2023.1208157.
[15]E. Myllyluoma et al., “Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy--a placebo-controlled, double-blind randomized pilot study,” Aliment Pharmacol Ther, vol. 21, no. 10, pp. 1263–1272, May 2005, doi: 10.1111/j.1365-2036.2005.02448.x.
[16]P. Malfertheiner et al., “Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report,” Gut, vol. 61, no. 5, pp. 646–664, May 2012, doi: 10.1136/gutjnl-2012-302084.
[17]P. Malfertheiner et al., “Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial,” Lancet, vol. 377, no. 9769, pp. 905–913, Mar. 2011, doi: 10.1016/S0140-6736(11)60020-2.
[18]J.-C. Yang, C.-W. Lu, and C.-J. Lin, “Treatment of Helicobacter pylori infection: Current status and future concepts,” World Journal of Gastroenterology, vol. 20, no. 18, pp. 5283–5293, May 2014, doi: 10.3748/wjg.v20.i18.5283.
[19]I. Thung et al., “Review article: the global emergence of Helicobacter pylori antibiotic resistance,” Aliment Pharmacol Ther, vol. 43, no. 4, pp. 514–533, Feb. 2016, doi: 10.1111/apt.13497.
[20]W. Z. Liu et al., “Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection,” Helicobacter, vol. 23, no. 2, p. e12475, Apr. 2018, doi: 10.1111/hel.12475.
[21]L. Yan et al., “Effect of Helicobacter pylori Eradication on Gastric Cancer Prevention: Updated Report From a Randomized Controlled Trial With 26.5 Years of Follow-up,” Gastroenterology, vol. 163, no. 1, pp. 154–162.e3, Jul. 2022, doi: 10.1053/j.gastro.2022.03.039.
[22]X.-Z. Zhou et al., “Large-scale, national, family-based epidemiological study on infection in China: the time to change practice for related disease prevention,” Gut, vol. 72, no. 5, pp. 855–869, May 2023, doi: 10.1136/gutjnl-2022-328965.
[23]K. Jia et al., “and immunotherapy for gastrointestinal cancer,” Innovation (Camb), vol. 5, no. 2, p. 100561, Mar. 2024, doi: 10.1016/j.xinn.2023.100561.
[24]X. Zhang et al., “Chitosan-modified molybdenum selenide mediated efficient killing of Helicobacter pylori and treatment of gastric cancer,” Int J Biol Macromol, vol. 275, no. Pt 1, p. 133599, Aug. 2024, doi: 10.1016/j.ijbiomac.2024.133599.
[25]H. Zhou, Y. Li, and W. Lu, “Treatment Effects of Bifidobacterium Quadruple Viable Tablets Combined With Quadruple Therapy on -Infected Peptic Ulcer in Children,” Clin Pediatr (Phila), vol. 64, no. 1, pp. 64–71, Jan. 2025, doi: 10.1177/00099228241248717.
[26]A. A. Agarwal et al., “Crystal structure of dihydroorotate dehydrogenase from Helicobacter pylori with bound flavin mononucleotide,” Acta Crystallogr F Struct Biol Commun, vol. 81, no. Pt 3, pp. 108–117, Mar. 2025, doi: 10.1107/S2053230X25000858.
[27]J. Tan et al., “pH-Responsive Polymeric Micelle Dynamic Complexes for Selective Killing of,” Biomacromolecules, vol. 24, no. 12, pp. 5551–5562, Dec. 2023, doi: 10.1021/acs.biomac.2c01374.
[28]L. Olmedo et al., “Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for infection between 2013 and 2021: results from the European registry on management (Hp-EuReg),” Gut, vol. 74, no. 1, pp. 15–25, Dec. 2024, doi: 10.1136/gutjnl-2024-332804.
[29]K. Kotilea et al., “Helicobacter pylori infection found during upper endoscopy performed for the diagnosis of celiac, inflammatory bowel diseases, and eosinophilic esophagitis: A multicenter pediatric European study,” Helicobacter, vol. 29, no. 3, p. e13092, May-Jun 2024, doi: 10.1111/hel.13092.
[30]M. Kato et al., “Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition,” Helicobacter, vol. 24, no. 4, p. e12597, Aug. 2019, doi: 10.1111/hel.12597.
[31]A. M. Asaad et al., “Susceptibility patterns and virulence genotypes of affecting eradication therapy outcomes among Egyptian patients with gastroduodenal diseases,” World J Gastroenterol, vol. 29, no. 19, pp. 2950–2960, May 2023, doi: 10.3748/wjg.v29.i19.2950.
[32] H. Demirci et al., “Helicobacter Pylori Colonization Density is an Important Risk Factor for Eradication Therapy,” J Gastrointestin Liver Dis, vol. 31, no. 2, pp. 163–167, Jun. 2022, doi: 10.15403/jgld-4238.
[33]H. Nordenstedt et al., “Helicobacter pylori-negative gastritis: prevalence and risk factors,” Am J Gastroenterol, vol. 108, no. 1, pp. 65–71, Jan. 2013, doi: 10.1038/ajg.2012.372.
[34]A. G. Gravina, R. M. Zagari, C. De Musis, L. Romano, C. Loguercio, and M. Romano, “and extragastric diseases: A review,” World J Gastroenterol, vol. 24, no. 29, pp. 3204–3221, Aug. 2018, doi: 10.3748/wjg.v24.i29.3204.
[35]R. Deguchi, T. Ueda, E. Teramura, Y. Arase, and T. Kagawa, “Colorectal mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori eradication treatment: a report of 5 cases,” J Gastrointestin Liver Dis, vol. 33, no. 3, pp. 426–428, Sep. 2024, doi: 10.15403/jgld-5672.
[36]C. Chen, “Science mapping: A systematic review of the literature,” J. Data Inf. Sci., vol. 2, no. 2, pp. 1–40, Mar. 2017, doi: 10.1515/jdis-2017-0006.
[37]N. J. van Eck and L. Waltman, “Software survey: VOSviewer, a computer program for bibliometric mapping,” Scientometrics, vol. 84, no. 2, pp. 523–538, Aug. 2010, doi: 10.1007/s11192-009-0146-3.
[38]V. Mahachai et al., “Helicobacter pylori management in ASEAN: The Bangkok consensus report,” J Gastroenterol Hepatol, vol. 33, no. 1, pp. 37–56, Jan. 2018, doi: 10.1111/jgh.13911.
[39]E. Goni et al., “The influence of gastric atrophy on Helicobacter pylori antibiotics resistance in therapy-naïve patients,” Front. Microbiol., vol. 13, p. 938676, Sep. 2022, doi: 10.3389/fmicb.2022.938676.
[40]P. Malfertheiner et al., “Management of infection: the Maastricht VI/Florence consensus report,” Gut, Aug. 2022, doi: 10.1136/gutjnl-2022-327745.
[41]N. García-Morales et al., “Diagnostic Tests Used in Europe: Results of over 34,000 Patients from the European Registry on Management,” J Clin Med, vol. 12, no. 13, Jun. 2023, doi: 10.3390/jcm12134363.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Interfaces
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
